2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 525

Low Interstitial Lung Disease Event Rate in Patients with Rheumatoid Arthritis: Pooled Post Hoc Analysis of Data from the Tofacitinib Clinical Development Program
Abstract Number: 526

Bronchiectasis in RA Is a Crucial Risk Factor of Hospitalised Pneumonia Associated with Bdmards As Well As Interstitial Lung Disease
Abstract Number: 527

Long-Term Follow up of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis
Abstract Number: 528

Progression in Interstitial Lung Disease – Comparison of Rheumatoid Arthritis with Idiopathic Pulmonary Fibrosis
Abstract Number: 529

Chest Computed Tomography Abnormalities in Patients with Rheumatoid Arthritis By Serologic Status
Abstract Number: 530

RA-Voice: Evaluating Laryngeal Involvement in Rheumatoid Arthritis Patients
Abstract Number: 531

Association of Rheumatoid Arthritis and Other Autoinmune Diseases
Abstract Number: 532

Relationship between Insulin Sensitivity and Beta Cell Secretion in Non-Diabetic Rheumatoid Arthritis Subjects
Abstract Number: 533

Association between Inflammation and Changes in Kidney Function in Patients with Early Rheumatoid Arthritis
Abstract Number: 534

Increased Insulin Resistance and Impaired Beta-Cell Function in Patients with Rheumatoid Arthritis: The Role of Glucocorticoid Therapy?
Abstract Number: 535

Is There Achilles Tendon Damage in Rheumatoid Arthritis Patients?
Abstract Number: 536

Prevalence and Relative Factors for Frailty in Patients with RA from a Prospective Observational Study
Abstract Number: 537

Increased Risk of Incident Chronic Kidney Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cohort Studies
Abstract Number: 538

Type 1 Diabetes in RA: Comparison with Type 2 and Its Association with RA Severity and Treatment
Abstract Number: 539

Thyroid Function in Early Versus Established Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].